PTPN11 and breast carcinoma: In highly aggressive mouse models of breast cancer and melanoma, simultaneous suppression of CSF-1R and PTPN11 to activate macrophages and promote phagocytosis may be an effective strategy for macrophage-based immunotherapy (210).